The mitogen-activated protein (MAP) kinase intracellular signaling pathways are involved in the regulation of various cellular functions.One of these pathways, the Raf/MEK/ERK pathway, plays a major role in the regulation of cellular growth, differentiation, and proliferation. The modulation of this cascade has been studied as a useful approach to treating proliferative disorders such as cancer.PD 184161 is a potent and selective inhibitor of MEK1/2 with an ICvalue that ranges from 10-100 nM. More effective at inhibiting phosphorylation of ERK1/2 than the selective MEK inhibitors, PD098059 and U0126, PD 184161 is useful both .in vitro and .in vivo for studying the pharmacological role of the Raf/MEK/ERK pathway.PD 184161 is structurally related to clinically-studied MEK inhibitors PD184352 (CI-1040) and PD 325901 and has been shown to inhibit cell proliferation, induce apoptosis, and possess anti-tumor activity in MEK-dependent cancers.

Additional Information

Synonyms	5-bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide
Product #	P-1713
CAS #	212631-67-9
Chemical Name	5-bromo-2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro-benzamide
Formula	C17H13BrClF2IN2O2
MW	557.6
Appearance	A crystalline Solid
Purity	98%
Solubility	Soluble in 10 mg/mL 100% ethanol, 30 mg/mL of DMSO or DMF; very sparnigly in aqueous buffers
Storage Temp	-20°C
Therapeutic Area	Oncological Disorders
Use	The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer

Additional Information

MDL Number	MFCD16038897
ChemACX	X1812350-3
InChI	InChI=1S/C17H13BrClF2IN2O2/c18-11-6-10(17(25)24-26-7-8-1-2-8)16(15(21)14(11)20)23-13-4-3-9(22)5-12(13)19/h3-6,8,23H,1-2,7H2,(H,24,25)
SMILES	O=C(c1cc(Br)c(F)c(F)c1Nc2ccc(I)cc2Cl)NOCC3CC3